Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Total Liabilities (2021 - 2025)

Verrica Pharmaceuticals has reported Total Liabilities over the past 5 years, most recently at $22.4 million for Q4 2025.

  • Quarterly results put Total Liabilities at $22.4 million for Q4 2025, down 65.02% from a year ago — trailing twelve months through Dec 2025 was $22.4 million (down 65.02% YoY), and the annual figure for FY2025 was $22.4 million, down 65.02%.
  • Total Liabilities for Q4 2025 was $22.4 million at Verrica Pharmaceuticals, down from $57.9 million in the prior quarter.
  • Over the last five years, Total Liabilities for VRCA hit a ceiling of $67.0 million in Q3 2024 and a floor of $3.8 million in Q1 2023.
  • Median Total Liabilities over the past 5 years was $47.7 million (2021), compared with a mean of $43.8 million.
  • Biggest five-year swings in Total Liabilities: tumbled 91.79% in 2023 and later skyrocketed 1608.38% in 2024.
  • Verrica Pharmaceuticals' Total Liabilities stood at $47.5 million in 2021, then crashed by 90.13% to $4.7 million in 2022, then soared by 1218.98% to $61.8 million in 2023, then rose by 3.49% to $64.0 million in 2024, then tumbled by 65.02% to $22.4 million in 2025.
  • The last three reported values for Total Liabilities were $22.4 million (Q4 2025), $57.9 million (Q3 2025), and $56.6 million (Q2 2025) per Business Quant data.